
## CITATION REPORT List of articles citing



DOI: 10.1038/ajg.2017.154 American Journal of Gastroenterology, 2017, 112, 988-1013.

Source: https://exaly.com/paper-pdf/66413804/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #   | Paper  | IF  | Citations |
|-----|--|-----|-----------|
| 348 | Proton Pump Inhibitors and Dementia: Deciphering the Data. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1809-1811  | 0.7 | 6         |
| 347 | Peptic Ulcer Disease. 2017, 35-47  |     |           |
| 346 | Limit chronic PPI use to manage dyspepsia, says new guideline. <b>2017</b> , 23, 2   |     |           |
| 345 | Rebamipide in Functional and Organic Dyspepsia: Sometimes the Best Offense Is a Good Defense. <b>2018</b> , 63, 1089-1090  |     | 3         |
| 344 | Less Is More: A Minimalist Approach to Endoscopy. <b>2018</b> , 154, 1993-2003   |     | 11        |
| 343 | Non-variceal upper gastrointestinal bleeding. <b>2018</b> , 4, 18020   |     | 43        |
| 342 | Comment on ACG and CAG Clinical Guidelines for Management of Dyspesia. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 623-624  | 0.7 |           |
| 341 | Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. <b>2018</b> , 3, 252-262 |     | 112       |
| 340 | Management of dyspepsia-The role of the ED Observation unit to optimize patient outcomes. <b>2018</b> , 36, 1733-1737  |     | O         |
| 339 | Helicobacter pylori Infection: An Update for the Internist in the Age of Increasing Global Antibiotic Resistance. <b>2018</b> , 131, 473-479   |     | 28        |
| 338 | Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report. <b>2018</b> , 154, 1140-1171.e1   |     | 155       |
| 337 | Test and Treat H. Pylori Eradication in Dyspepsia-"A Bridge too Far" in the Concensus?. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 144-145   | 0.7 | 0         |
| 336 | Toll-like receptors-mediated pathways activate inflammatory responses in the esophageal mucosa of adult eosinophilic esophagitis. <b>2018</b> , 9, 147   |     | 20        |
| 335 | Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States. <b>2018</b> , 16, 992-1002.e6  |     | 107       |
| 334 | Cost Effectiveness of Biomarker Tests for Irritable Bowel Syndrome With Diarrhea: A Framework for Payers. <b>2018</b> , 16, 1434-1441.e21  |     | 4         |
| 333 | Response to Marlicz et al. American Journal of Gastroenterology, 2018, 113, 781  | 0.7 |           |
| 332 | Assessment of Pharmaceutical Company and Device Manufacturer Payments to Gastroenterologists and Their Participation in Clinical Practice Guideline Panels. <b>2018</b> , 1, e186343                                 |     | 9         |

## (2018-2018)

| 331 | [Guideline Recommendation for Endpoints Used in Clinical Trials for Functional Dyspepsia]. <b>2018</b> , 72, 170-178  | 4  |
|-----|---|----|
| 330 | Insights into the evaluation and management of dyspepsia: recent developments and new guidelines. <b>2018</b> , 11, 1756284818805597  | 13 |
| 329 | Occurrence and predictors of metaplastic atrophic gastritis in a nation-wide consecutive endoscopic population presenting with upper gastrointestinal symptoms. <b>2018</b> , 30, 1291-1296 | 12 |
| 328 | Gastroduodenal motility disorders. <b>2018</b> , 34, 428-435  | 15 |
| 327 | New developments in the treatment of gastroparesis and functional dyspepsia. 2018, 43, 111-117  | 52 |
| 326 | Current understanding and management of infection: an updated appraisal. 2018, 7,   | 17 |
| 325 | Imipramine for functional dyspepsia: a 60-year journey. <b>2018</b> , 3, 815-817  |    |
| 324 | Low-dose imipramine for refractory functional dyspepsia: a randomised, double-blind, placebo-controlled trial. <b>2018</b> , 3, 837-844   | 21 |
| 323 | New Approaches to Diagnosis and Treatment of Functional Dyspepsia. <b>2018</b> , 20, 55   | 15 |
| 322 | Canadian Association of Gastroenterology Statement on the Putative Link Between Proton Pump Inhibitor Treatment and Gastric Cancer after Eradication. <b>2018</b> , 1, 155-158              | 1  |
| 321 | Functional Dyspepsia - A Revolution in Management. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 1420-1422   | 7  |
| 320 | Irritable bowel syndrome and functional dyspepsia: what can epidemiology tell us about etiology?. <b>2018</b> , 12, 633-635   | 6  |
| 319 | The fourth Mexican consensus on Helicobacter pylori. <b>2018</b> , 83, 325-341  | 11 |
| 318 | The Diagnosis and Treatment of Functional Dyspepsia. <b>2018</b> , 115, 222-232   | 36 |
| 317 | The fourth Mexican consensus on Helicobacter pylori. <b>2018</b> , 83, 325-341  | 0  |
| 316 | IVTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION. <b>2018</b> , 55, 97-121  | 22 |
| 315 | Funktionelle Dyspepsie. <b>2018</b> , 13, 98-105  |    |
| 314 | A Simple Pre-endoscopy Score for Predicting Risk of Malignancy in Patients with Dyspepsia: A 5-Year Prospective Study. <b>2018</b> , 63, 3442-3447  | 2  |

| 313 | Proton pump inhibitors and suppression of duodenal eosinophilia in functional dyspepsia. <b>2019</b> , 68, 1339-134   | <b>10</b> 18 |
|-----|---|--------------|
| 312 | Editorial: the overlap between dyspepsia and gastro-oesophageal reflux-is duodenal eosinophilia the missing link?. <b>2019</b> , 50, 454-455  | O            |
| 311 | Tangible pathologies in functional dyspepsia. <b>2019</b> , 40-41, 101650   | 11           |
| 310 | Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. <b>2019</b> , 157, 682-691.e2                                       | 181          |
| 309 | Helicobacter pylori eradication in dyspepsia: New evidence for symptomatic benefit. <b>2019</b> , 40-41, 101637   | 4            |
| 308 | Validation of MARK quadrant scoring system for early upper gastrointestinal endoscopy to detect gastric neoplasms in Chinese dyspeptic patients: A retrospective study. <b>2019</b> , 23, 101-107 |              |
| 307 | Functional Dyspepsia. <b>2019</b> , 239-244   |              |
| 306 | Equibiotic-GI Consumption Improves Intestinal Microbiota in Subjects with Functional Dyspepsia. <b>2019</b> , 14, 220-227   |              |
| 305 | Eradication Therapy for Functional Dyspepsia: A Meta-Analysis by Region and Prevalence. 2019, 8,  | 17           |
| 304 | Drugs under development for the treatment of functional dyspepsia and related disorders. <b>2019</b> , 28, 871-889  | 11           |
| 303 | Peptic ulcer disease. <b>2019</b> , 367, l5495  | 19           |
| 302 | Influence of itopride and domperidone on gastric tone and on the perception of gastric distention in healthy subjects. <b>2019</b> , 31, e13544   | 2            |
| 301 | Helicobacter pylori infection among patients presenting with dyspepsia at a primary care setting in Cameroon: seroprevalence, five-year trend and predictors. <b>2019</b> , 19, 30                | 5            |
| 300 | Barrett oesophagus. <b>2019</b> , 5, 35   | 42           |
| 299 | Electroacupuncture plus on-demand gastrocaine for refractory functional dyspepsia: Pragmatic randomized trial. <b>2019</b> , 34, 2077-2085  | 7            |
| 298 | Determinants of diagnostic delay in autoimmune atrophic gastritis. <b>2019</b> , 50, 167-175  | 31           |
| 297 | Heartburn. <b>2019</b> , 107-120  |              |
| 296 | Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics. <b>2019</b> , 157, 44-53   | 116          |

| 295 | [Functional Dyspepsia]. <b>2019</b> , 73, 77-83   | 7  |
|-----|---|----|
| 294 | Gastrointestinal Health and Healthy Aging. <b>2019</b> , 67-79  |    |
| 293 | Management of Helicobacter pylori infection at the primary care level. The implementation of specific counseling improves eradication rates. <b>2019</b> , 24, e12586                 | 5  |
| 292 | Gastroparesis Versus Functional Dyspepsia: Still Running on Emptying. <b>2019</b> , 64, 1064-1066   | 1  |
| 291 | The Unfulfilled Promise of Prokinetics for Functional Dyspepsia/Postprandial Distress Syndrome.  American Journal of Gastroenterology, <b>2019</b> , 114, 204-206                     | 12 |
| 290 | Recent understanding of the pathophysiology of functional dyspepsia: role of the duodenum as the pathogenic center. <b>2019</b> , 54, 305-311   | 25 |
| 289 | Functional Dyspepsia. <b>2019</b> , 127-138   |    |
| 288 | Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. <b>2019</b> , 9, 2282 | 29 |
| 287 | Peptic Ulcer Disease. <b>2019</b> , 1-31  | 0  |
| 286 | Can mean platelet volume indicate positivity and severity of gastric inflammation? An original study and review of the literature. <b>2019</b> , 58, 576-582                          | 1  |
| 285 | Buspirone for the Management of Functional Dyspepsia With Rapid Gastric Emptying. <b>2019</b> , 6, e00280   | 1  |
| 284 | Functional Dyspepsia in the Elderly. <b>2019</b> , 21, 54   | 1  |
| 283 | Depression, anxiety and stress symptoms in patients presenting with dyspepsia at a regional hospital in KwaZulu-Natal province. <b>2019</b> , 25, 1382                                | 1  |
| 282 | Effects of comfort care on symptoms, gastric motility, and mental state of patients with functional dyspepsia. <b>2019</b> , 98, e16110   | 9  |
| 281 | The Clinician's Guide to Proton-Pump Inhibitor Discontinuation. <b>2019</b> , 53, 553-559   | 1  |
| 280 | PEPTIC ULCER DISEASE. <b>2019</b> , 42, 451-454   | 16 |
| 279 | The Efficacy of Hypnotherapy in the Treatment of Functional Dyspepsia. <b>2019</b> , 26, e704-e713  | 10 |
| 278 | Effectiveness of management strategies for uninvestigated dyspepsia: systematic review and network meta-analysis. <b>2019</b> , 367, l6483  | 17 |

| 277 | Histamine H2 antagonists for functional dyspepsia: A protocol for a systematic review and meta-analysis. <b>2019</b> , 98, e18128   |   | О  |
|-----|---|---|----|
| 276 | Proton Pump Inhibitors in the Elderly, Balancing Risk and Benefit: an Age-Old Problem. <b>2019</b> , 21, 65   |   | 7  |
| 275 | A multicentric Spanish study on the characteristics and survival of gastric adenocarcinoma under the age of 60. <b>2019</b> , 42, 595-603   |   |    |
| 274 | Optimization of C-urea breath test threshold levels for the detection of Helicobacter pylori infection in a national referral laboratory. <b>2019</b> , 33, e22674  |   | 9  |
| 273 | Postprandial distress syndrome: stratification and management. <b>2019</b> , 13, 37-46  |   | 12 |
| 272 | Prokinetics for Functional Dyspepsia: A Systematic Review and Meta-Analysis of Randomized Control Trials. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 233-243                                      | 7 | 46 |
| 271 | Thailand Dyspepsia Guidelines: 2018. <b>2019</b> , 25, 15-26  |   | 9  |
| 270 | Associated risks of proton pump inhibitors and their influence on prescribing habits: is change truly warranted?. <b>2019</b> , 32,   |   |    |
| 269 | Five common errors to avoid in clinical practice: the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO) Choosing Wisely Campaign. <b>2019</b> , 14, 301-308                                   |   | 2  |
| 268 | Association between Functional Dyspepsia and Gastric Depressive Erosions in Japanese Subjects. <b>2019</b> , 58, 321-328  |   | 4  |
| 267 | Higher clinical suspicion is needed for prompt diagnosis of esophageal adenocarcinoma in young patients. <b>2019</b> ,  |   | 4  |
| 266 | Dual histamine blockade for the treatment of adult functional dyspepsia: a single centre experience. <b>2020</b> , 69, 966  |   | 9  |
| 265 | Nurse-Led, Shared Medical Appointments for Common Gastrointestinal Conditions-Improving Outcomes Through Collaboration With Primary Care in the Medical Home: A Prospective Observational Study. <b>2020</b> , 3, 59-66 |   | 1  |
| 264 | Of hearts, minds, and guts: difficulties in diagnosing heart failure in the young. <b>2020</b> , 22, 8-11   |   | O  |
| 263 | What Causes Functional Gastrointestinal Disorders? A Proposed Disease Model. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 41-48   | 7 | 40 |
| 262 | Analysis of the Influence of Interleukin-1©ene Polymorphism on Gastric Inflammatory Response and Precancerous Lesions Development in Patients with Functional Dyspepsia. <b>2020</b> , 49, 585-596                      |   | 2  |
| 261 | Current and emerging therapeutic options for the management of functional dyspepsia. <b>2020</b> , 21, 365-370  | 6 | 7  |
| 260 | Reply. <b>2020</b> , 158, 1175-1176   |   | 1  |

## (2020-2020)

| 259                             | Decreasing Overall and Inappropriate Proton Pump Inhibitor Use: Perspective From a Large Safety-Net Healthcare System. <b>2020</b> , 18, 763-766.e2   | 7             |
|---------------------------------|---|---------------|
| 258                             | Reply. <b>2020</b> , 158, 285-286   |               |
| 257                             | Use of Evidence-Based Herbal Medicines for Patients with Functional Gastrointestinal Disorders: A Conceptional Framework for Risk-Benefit Assessment and Regulatory Approaches. <b>2020</b> , 38, 269-279   | 5             |
| 256                             | Consumption of medicines used for gastric acid-related disorders in Australia and South Korea: a cross-country comparison. <b>2020</b> , 76, 547-555  | 4             |
| 255                             | Functional dyspepsia. <b>2020</b> , 281-292   |               |
| 254                             | Controversies Around Measuring Drug Toxicity: US Food and Drug Administration and Gastrointestinal Perspectives. <b>2020</b> , 158, 22-27   | 2             |
| 253                             | Novel concepts in the pathophysiology and treatment of functional dyspepsia. <b>2020</b> , 69, 591-600  | 65            |
| 252                             | Non-pharmacological Approach in the Management of Functional Dyspepsia. <b>2020</b> , 26, 6-15  | 7             |
| 251                             | Antidepressant use in gastroenterology: Overcoming hurdles. <b>2020</b> , 32, e13982  |               |
|                                 |   |               |
| 250                             | Integrated care for disorders of gut-brain interaction. <b>2020</b> , 5, 876-877  | 1             |
| 250<br>249                      | Integrated care for disorders of gut-brain interaction. <b>2020</b> , 5, 876-877  Gastroparesis and functional dyspepsia: different diseases or different ends of the spectrum?. <b>2020</b> , 36, 509-517  | 6             |
|                                 | Gastroparesis and functional dyspepsia: different diseases or different ends of the spectrum?. <b>2020</b>  |               |
| 249                             | Gastroparesis and functional dyspepsia: different diseases or different ends of the spectrum?. <b>2020</b> , 36, 509-517  | 6             |
| 249                             | Gastroparesis and functional dyspepsia: different diseases or different ends of the spectrum?. <b>2020</b> , 36, 509-517  Functional dyspepsia. <b>2020</b> , 396, 1689-1702  | 6<br>83       |
| 249<br>248<br>247               | Gastroparesis and functional dyspepsia: different diseases or different ends of the spectrum?. 2020, 36, 509-517  Functional dyspepsia. 2020, 396, 1689-1702  Functional Dyspepsia: Diagnostic and Therapeutic Approaches. 2020, 80, 1319-1336  | 6<br>83<br>13 |
| 249<br>248<br>247<br>246        | Gastroparesis and functional dyspepsia: different diseases or different ends of the spectrum?. 2020, 36, 509-517  Functional dyspepsia. 2020, 396, 1689-1702  Functional Dyspepsia: Diagnostic and Therapeutic Approaches. 2020, 80, 1319-1336  Update on the Management of Infection. 2020, 18, 1-12  Comparison of a Novel Herbal Medicine and Omeprazole in the Treatment of Functional Dyspepsia:   | 6<br>83<br>13 |
| 249<br>248<br>247<br>246<br>245 | Gastroparesis and functional dyspepsia: different diseases or different ends of the spectrum?. 2020, 36, 509-517  Functional dyspepsia. 2020, 396, 1689-1702  Functional Dyspepsia: Diagnostic and Therapeutic Approaches. 2020, 80, 1319-1336  Update on the Management of Infection. 2020, 18, 1-12  Comparison of a Novel Herbal Medicine and Omeprazole in the Treatment of Functional Dyspepsia: A Randomized Double-Blinded Clinical Trial. 2020, 2020, 5152736 | 6<br>83<br>13 |

| 241 | Acid inhibitors and allergy: comorbidity, causation and confusion. <b>2020</b> , 11, 3950  | 1  |
|-----|--|----|
| 240 | High dose PPI-amoxicillin dual therapy for the treatment of infection: a systematic review with meta-analysis. <b>2020</b> , 13, 1756284820937115  | 8  |
| 239 | Frequency and clinical characteristics of early gastric cancer in comparison to advanced gastric cancer in a health area of Spain. <b>2020</b> , 43, 506-514   |    |
| 238 | Systematic review with meta-analysis: age-related malignancy detection rates at upper gastrointestinal endoscopy. <b>2020</b> , 13, 1756284820959225   | 1  |
| 237 | [Appropriate use of proton pump inhibitors (PPI)]. <b>2020</b> , 162, 58-65  |    |
| 236 | Electroacupuncture for the treatment of functional dyspepsia: A systematic review and meta-analysis. <b>2020</b> , 99, e23014  | 10 |
| 235 | An Herbal Formulation of Jiawei Xiaoyao for the Treatment of Functional Dyspepsia: A Multicenter, Randomized, Placebo-Controlled, Clinical Trial. <b>2020</b> , 11, e00241   | 6  |
| 234 | Frequency and clinical characteristics of early gastric cancer in comparison to advanced gastric cancer in a health area of Spain. <b>2020</b> , 43, 506-514   | 1  |
| 233 | IFSO Position Statement on the Role of Esophago-Gastro-Duodenal Endoscopy Prior to and after Bariatric and Metabolic Surgery Procedures. <b>2020</b> , 30, 3135-3153   | 41 |
| 232 | Is administration of proton pump inhibitors in functional dyspepsia worth the risk of developing gastric cancer: a Markov model to bridge the gap between scientific evidence and clinical practice. <b>2020</b> , 10, e031091 | 2  |
| 231 | Current Perspectives in Atrophic Gastritis. <b>2020</b> , 22, 38   | 11 |
| 230 | Duodenal eosinophils as predictors of symptoms in coeliac disease: a comparison of coeliac disease and non-coeliac dyspeptic patients with controls. <b>2020</b> , 55, 780-784   | 3  |
| 229 | How to advise patients on the risk of chronic proton pump inhibitor therapy. <b>2020</b> , 36, 317-322   | 5  |
| 228 | Proton Pump Inhibitors: for What and for How Long. <b>2020</b> , 2, 719-726  |    |
| 227 | Recent Advances in the Pathogenesis and Treatment of Functional Dyspepsia with Focus on the Duodenum. <b>2020</b> , 75, 112  |    |
| 226 | Risk of Serious Ventricular Arrhythmia in Users of Gastrointestinal Medications: A Retrospective Cohort Study in China. <b>2020</b> , 37, 1564-1578  | 1  |
| 225 | Helicobacter pylori: A Review of Current Diagnostic and Management Strategies. <b>2020</b> , 65, 1917-1931   | 29 |
| 224 | Peptic Ulcer Disease. <b>2020</b> ,  |    |

| 223                             | Functional Dyspepsia: A Narrative Review With a Focus on Sex-Gender Differences. <b>2020</b> , 26, 322-334  | 12                      |
|---------------------------------|---|-------------------------|
| 222                             | Prevalence and Characteristics of Abdominal Pain in the United States. <b>2021</b> , 19, 1864-1872.e5   | 4                       |
| 221                             | Prevalence of Non-Celiac Gluten Sensitivity in Patients with Refractory Functional Dyspepsia: a Randomized Double-blind Placebo Controlled Trial. <b>2020</b> , 10, 2401  | 17                      |
| 220                             | Preoperative Helicobacter pylori Screening and Treatment in Patients Undergoing Laparoscopic Sleeve Gastrectomy. <b>2020</b> , 30, 2816-2820  | 3                       |
| 219                             | Acupuncture of different treatment frequency in postprandial distress syndrome: A pilot randomized clinical trial. <b>2020</b> , 32, e13812   | 4                       |
| 218                             | Clinical Practice Guidelines for Functional Dyspepsia in Korea. <b>2020</b> , 26, 29-50   | 20                      |
| 217                             | Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. <b>2020</b> , 69, 617-629   | 35                      |
| 216                             | A current clinical overview of atrophic gastritis. <b>2020</b> , 14, 93-102   | 19                      |
| 215                             | Exosomal hsa-miR-933 in Gastric Juice as a Potential Biomarker for Functional Dyspepsia. <b>2020</b> , 65, 3493-350   | 01 2                    |
|                                 |   |                         |
| 214                             | Duodenal inflammation: an emerging target for functional dyspepsia?. <b>2020</b> , 24, 511-523  | 17                      |
| 214                             | Duodenal inflammation: an emerging target for functional dyspepsia?. <b>2020</b> , 24, 511-523  Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. <b>2020</b> , 30, 903-915   | 17                      |
|                                 | Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. <b>2020</b>   |                         |
| 213                             | Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. <b>2020</b> , 30, 903-915  Efficacy and Safety of Clidinium/Chlordiazepoxide as an Add-on Therapy in Functional Dyspepsia: A  | 15                      |
| 213                             | Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. <b>2020</b> , 30, 903-915  Efficacy and Safety of Clidinium/Chlordiazepoxide as an Add-on Therapy in Functional Dyspepsia: A Randomized, Controlled, Trial. <b>2020</b> , 26, 259-266  Clinical study on post evaluation after listing of Qizhi Weitong granules: Study protocol clinical trial   | 15<br>3                 |
| 213                             | Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. 2020, 30, 903-915  Efficacy and Safety of Clidinium/Chlordiazepoxide as an Add-on Therapy in Functional Dyspepsia: A Randomized, Controlled, Trial. 2020, 26, 259-266  Clinical study on post evaluation after listing of Qizhi Weitong granules: Study protocol clinical trial (SPIRIT compliant). 2020, 99, e19758  Proton pump inhibitors enhance intestinal permeability via dysbiosis of gut microbiota under  | 15<br>3<br>2            |
| 213<br>212<br>211<br>210        | Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. 2020, 30, 903-915  Efficacy and Safety of Clidinium/Chlordiazepoxide as an Add-on Therapy in Functional Dyspepsia: A Randomized, Controlled, Trial. 2020, 26, 259-266  Clinical study on post evaluation after listing of Qizhi Weitong granules: Study protocol clinical trial (SPIRIT compliant). 2020, 99, e19758  Proton pump inhibitors enhance intestinal permeability via dysbiosis of gut microbiota under stressed conditions in mice. 2020, 32, e13841  | 15<br>3<br>2            |
| 213<br>212<br>211<br>210<br>209 | Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. 2020, 30, 903-915  Efficacy and Safety of Clidinium/Chlordiazepoxide as an Add-on Therapy in Functional Dyspepsia: A Randomized, Controlled, Trial. 2020, 26, 259-266  Clinical study on post evaluation after listing of Qizhi Weitong granules: Study protocol clinical trial (SPIRIT compliant). 2020, 99, e19758  Proton pump inhibitors enhance intestinal permeability via dysbiosis of gut microbiota under stressed conditions in mice. 2020, 32, e13841  The Association between Infection and Irritable Bowel Syndrome: A Meta-Analysis. 2020, 17,  Leaving No Stone Unturned in the Search for Adverse Events Associated With Use of Proton Pump | 15<br>3<br>2<br>11<br>4 |

205 Update on Indigestion. **2021**, 105, 19-30

| 204 | Design characteristics of comparative effectiveness trials for the relief of symptomatic dyspepsia: A systematic review. <b>2021</b> , 10, 100663   | 1  |
|-----|---|----|
| 203 | Proton Pump Inhibitors Reduce Duodenal Eosinophilia, Mast Cells, and Permeability in Patients With Functional Dyspepsia. <b>2021</b> , 160, 1521-1531.e9  | 19 |
| 202 | Knowledge, Attitude, and Practice Survey of Gastroparesis in Asia by Asian Neurogastroenterology and Motility Association. <b>2021</b> , 27, 46-54  | 3  |
| 201 | Discontinuation of Long-Term Proton Pump Inhibitor Therapy. <b>2021</b> , 28, e131-e135   | 1  |
| 200 | Effectiveness of Ayurveda treatment in Urdhwaga Amlapitta: A clinical evaluation. <b>2021</b> , 12, 87-92   | 1  |
| 199 | Peptic Ulcer Disease. <b>2021</b> , 1565-1595   |    |
| 198 | Research Progress on the Relationship between Intestinal Flora Disorders and Functional Dyspepsia. <b>2021</b> , 11, 3225-3231  |    |
| 197 | Efficacy and Safety of DWJ1252 Compared With Gasmotin Treatment: Once Met 3 Times Tablets. <b>2021</b> , 27, 3-4  |    |
| 196 | Management of functional dyspepsia in 2020: a clinical point of view. <b>2020</b> , 66, 331-342   | 8  |
| 195 | Chronic gastritis according to age and in Thailand: histopathological patterns. 2021, 56, 228-233   | 3  |
| 194 | Deconstructing stigma as a barrier to treating DGBI: Lessons for clinicians. <b>2021</b> , 33, e14080   | 12 |
| 193 | Helicobacter pylori-associated gastritis phenotypes in a South-Western Nigerian population. <b>2021</b> , 13, 6   |    |
| 192 | Efficacy of modified Banxia Xiexin decoction in the management of Wei-Pi syndrome (postprandial distress syndrome): study protocol for a randomized, waitlist-controlled trial. <b>2021</b> , 22, 135 | 1  |
| 191 | Long-Term Implications of GERD After Sleeve Gastrectomy. <b>2021</b> , 9, 1   | 3  |
| 190 | The Brain-Gut-Microbiotal Axis: A framework for understanding functional GI illness and their therapeutic interventions. <b>2021</b> , 84, 1-9  | 13 |
| 189 | Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN). <b>2021</b> , 13,                                     | 1  |
| 188 | The Positive Association between Proton Pump Inhibitors and Clostridium Difficile Infection. <b>2021</b> , 12,  | 3  |

| 187                      | Evidence-Based Guidelines for the Treatment of Infection in Korea 2020. <b>2021</b> , 15, 168-195   |     | 15          |
|--------------------------|---|-----|-------------|
| 186                      | Management of Dyspepsia and Gastroparesis in Patients with Diabetes. A Clinical Point of View in the Year 2021. <b>2021</b> , 10,   |     | 2           |
| 185                      | Single-Center Review of Appropriateness and Utilization of Upper Endoscopy in Dyspepsia in the United States. <b>2021</b> , 14, 81-86   |     | O           |
| 184                      | Clinical Practice Guidelines for the Treatment of Functional Dyspepsia in Korea. <b>2021</b> , 96, 116-138  |     | 4           |
| 183                      | The yield of upper gastrointestinal endoscopy in patients below 60 years and without alarm symptoms presenting with dyspepsia. <b>2021</b> , 56, 740-746  |     | 1           |
| 182                      | United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. <b>2021</b> , 9, 307-331   |     | 20          |
| 181                      | Pharmacomagnetography to evaluate the performance of magnetic enteric-coated tablets in the human gastrointestinal tract. <b>2021</b> , 161, 50-55  |     | 1           |
| 180                      | Proton Pump Inhibitors in 2021: Pros, Cons, and Everything in Between. <b>2021</b> , 1, 145-151   |     |             |
| 179                      | Dyspepsia: Treatment Options Directed to Specific Targets. <b>2021</b> , 19, 434-442  |     |             |
|                          |   |     |             |
| 178                      | ASMBS position statement on the rationale for performance of upper gastrointestinal endoscopy before and after metabolic and bariatric surgery. <b>2021</b> , 17, 837-847   |     | 14          |
| 178                      |   | 0.7 | 14<br>4     |
|                          | before and after metabolic and bariatric surgery. <b>2021</b> , 17, 837-847  Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options.   | 0.7 |             |
| 177                      | before and after metabolic and bariatric surgery. 2021, 17, 837-847  Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options.  American Journal of Gastroenterology, 2021, 116, 1587-1600  Clinically significant endoscopic findings in patients of dyspepsia with no warning symptoms: A  | 0.7 |             |
| 177<br>176               | before and after metabolic and bariatric surgery. 2021, 17, 837-847  Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options.  American Journal of Gastroenterology, 2021, 116, 1587-1600  Clinically significant endoscopic findings in patients of dyspepsia with no warning symptoms: A cross-sectional study. 2021, 9, 3597-3606  The management of upper gastrointestinal symptoms: A study on community pharmacies in Italy.  | 0.7 | 4           |
| 177<br>176<br>175        | Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options.  American Journal of Gastroenterology, 2021, 116, 1587-1600  Clinically significant endoscopic findings in patients of dyspepsia with no warning symptoms: A cross-sectional study. 2021, 9, 3597-3606  The management of upper gastrointestinal symptoms: A study on community pharmacies in Italy. 2021, 68, 401-409  Diagnostic Delay in Patients with Eosinophilic Gastritis and/or Duodenitis: A Population-Based   | 0.7 | 1           |
| 177<br>176<br>175        | Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options.  American Journal of Gastroenterology, 2021, 116, 1587-1600  Clinically significant endoscopic findings in patients of dyspepsia with no warning symptoms: A cross-sectional study. 2021, 9, 3597-3606  The management of upper gastrointestinal symptoms: A study on community pharmacies in Italy. 2021, 68, 401-409  Diagnostic Delay in Patients with Eosinophilic Gastritis and/or Duodenitis: A Population-Based Study. 2021, 9, 2050-2059.e20   | 0.7 | 1 7         |
| 177<br>176<br>175<br>174 | Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options.  American Journal of Gastroenterology, 2021, 116, 1587-1600  Clinically significant endoscopic findings in patients of dyspepsia with no warning symptoms: A cross-sectional study. 2021, 9, 3597-3606  The management of upper gastrointestinal symptoms: A study on community pharmacies in Italy. 2021, 68, 401-409  Diagnostic Delay in Patients with Eosinophilic Gastritis and/or Duodenitis: A Population-Based Study. 2021, 9, 2050-2059.e20  What Is New in Diagnosis. An Overview. 2021, 10, | 0.7 | 4<br>1<br>7 |

| 169 | Epidemiological and clinical features of functional dyspepsia in a region with a high incidence of esophageal cancer in China. <b>2021</b> , 134, 1422-1430                                       | 2  |
|-----|---|----|
| 168 | Rikkunshito as a Therapeautic Agent for Functional Dyspepsia and its Prokinetic and Non-Prokinetic Effects. <b>2021</b> , 12, 640576  | 3  |
| 167 | Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea: 2020 Revised Edition. <b>2021</b> , 96, 160-189  |    |
| 166 | Correlation between the symptoms of upper gastrointestinal disease and endoscopy findings: Implications for clinical practice. <b>2021</b> , 16, 395-401  |    |
| 165 | Are psychological interventions effective in treating functional dyspepsia? A systematic review and meta-analysis. <b>2021</b> , 36, 2047-2057  | 6  |
| 164 | Dyspepsia-challenge in primary care gastroenterology. <b>2021</b> ,   | О  |
| 163 | Effectiveness and Safety of A Nutraceutical Formulation for the Treatment of Functional Dyspepsia in Primary Care. <b>2021</b> , 16, 329-334  | O  |
| 162 | Gastroscopy in younger patients: an analysis of referrals and pathologies. <b>2021</b> , 33, 1266-1273  | О  |
| 161 | Pancreatic Fibrosis (Early Chronic Pancreatitis) as Emerging Diagnosis in Structural Causes of Dyspepsia: Evidence from Endoscopic Ultrasonography and Shear Wave Elastography. <b>2021</b> , 11, |    |
| 160 | The fear of gastric cancer in patients with dyspepsia - challenge in specialist care gastroenterology. <b>2021</b> ,  | О  |
| 159 | The Prevalence of the Celiac Disease in Patients with Dyspepsia: A Systematic Review and Meta-Analysis. <b>2021</b> , 1   | 0  |
| 158 | Clinical Relevance of Infection. <b>2021</b> , 10,  | 11 |
| 157 | Rational treatment of patients with functional dyspepsia. <b>2021</b> , 93, 982-985   | 1  |
| 156 | Functional dyspepsia: A critical appraisal of the European consensus from a global perspective. <b>2021</b> , 33, e14216  | О  |
| 155 | Diffi culties of diff erential diagnosis in functional dyspepsia. <b>2021</b> , 99, 208-212   |    |
| 154 | United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. <b>2021</b> , 33, e14238                             | 4  |
| 153 | Approach to Abdominal Imaging in 2022. <b>2021</b> , 39, 745-767  | 0  |
| 152 | The role of the occupational physician in controlling gastric cancer attributable to infection: A review <b>2021</b> , 24, 101527   | 2  |

| 151 | Herbal medicine for functional dyspepsia: Network meta-analysis of placebo-controlled randomised trials. <b>2022</b> , 283, 114665  | 2  |
|-----|---|----|
| 150 | Gastroenterology. <b>2021</b> , 279-294   |    |
| 149 | Spectrum and pattern of distribution of findings in patients with dyspepsia undergoing oesophago-gastro-duodenoscopy at a Tertiary Hospital in Ibadan, south west, Nigeria. <b>2021</b> , 57, 151-156                         |    |
| 148 | Distinguishing between functional dyspepsia and gastroparesis: Does it matter?. <b>2021</b> , 481-493   |    |
| 147 | Functional Dyspepsia. <b>2019</b> , 155-172   | 4  |
| 146 | Guia de prEica clEica: sinais e sintomas do trato gastrointestinal: azia (acidez/pirose) e dispepsia. <b>2020</b> ,   | 1  |
| 145 | Patient symptom experience prior to a diagnosis of oesophageal or gastric cancer: a multi-methods study. <b>2020</b> , 4,   | 6  |
| 144 | Prevention of overuse: A view on upper gastrointestinal endoscopy. <b>2019</b> , 25, 178-189  | 15 |
| 143 | Effects and mechanisms of acupuncture and electroacupuncture for functional dyspepsia: A systematic review. <b>2020</b> , 26, 2440-2457   | 12 |
| 142 | Role of gut microbiota via the gut-liver-brain axis in digestive diseases. <b>2020</b> , 26, 6141-6162  | 17 |
| 141 | Effects of the Rome IV Criteria to Functional Dyspepsia Symptoms in Saudi Arabia: Epidemiology and Clinical Practice. <b>2020</b> , 76, 304-313   | 3  |
| 140 | Evidence-based Guidelines for the Treatment of Helicobacter pylori Infection in Korea: 2020 Revised Edition. <b>2020</b> , 20, 261-287  | 7  |
| 139 | Endoscopic Findings in Patients With Uninvestigated Dyspepsia: A Retrospective Study From Qatar. <b>2020</b> , 12, e11166   | 1  |
| 138 | Association between dyspeptic symptoms and endoscopic findings based on the Kyoto classification of gastritis in Japanese male <b>2022</b> , 70, 79-85  | O  |
| 137 | A Survey of Methodologies for Assessing Mast Cell Density and Activation in Patients with Functional Abdominal Pain Disorders. <b>2021</b> , 3, 142-155   | 2  |
| 136 | Prevalence, symptoms and risk factor profile of rumination syndrome and functional dyspepsia: a population-based study. <b>2021</b> , 54, 1416-1431   | 2  |
| 135 | Characteristics of gastric precancerous conditions and Helicobacter pylori infection among dyspeptic patients in north-eastern Iran: is endoscopic biopsy and histopathological assessment necessary?. <b>2021</b> , 21, 1143 | 1  |
| 134 | Functional Dyspepsia and the Irritable Bowel Syndrome. <b>2019</b> , 1-11   |    |

A Diagnostic Approach to Dyspepsia. 2019, 125-140 133 Frequency of Determining the Active Forms of Helicobacter Infection in Patients with Chronic 132 Non-Throphic Gastritis with Various Forms of Biliary Dyskinesia. 2019, 4, 136-141 Functional dyspepsia: from pathogenesis to therapeutic aspects. 2019, 18-25 131 1 Can Eradication of Helicobacter pylori Improve the Symptoms of Functional Dyspepsia?. 2019, 19, 79-80 130 Helicobacter pylori as a risk factor for gastric cancer: the evidence and primary prevention strategy. 129 3 2019. 47. 535-547 A multicentric Spanish study on the characteristics and survival of gastric adenocarcinoma under 128 the age of 60. **2019**, 42, 595-603 Gastritis, Esophagitis and Peptic Ulcer Disease. 2020, 1-10 127 Tratamiento inicial y del fracaso en la erradicacia de la infeccia por Helicobacter pylori. 2020, 13, 106-110 126 Effects and mechanisms of acupuncture and electroacupuncture for functional dyspepsia: A 125 systematic review. 2020, 26, 2439-2456 Birinci Basamakta Dispepsi Ikayeti Olan Erillin Hastaya Klinik Yaklalla. 124 Dispeptik yakāmalarla acil servise macat eden hastalarda etiyolojik dearlendirme. 1-0 123 70-Year-Old Man With Chronic Nausea and Vomiting. 2021, 96, 3142-3146 122 Value of age and alarm features for predicting upper gastrointestinal malignancy in patients with 121 O dyspepsia: an endoscopic database review of 4664 patients in Thailand. 2021, 11, e052522 Impact of pharmacy-supported interventions on proportion of patients receiving non-indicated acid 120 2 suppressive therapy upon discharge: A systematic review and meta-analysis. 2020, 15, e0243134 Rome III, Rome IV, and Potential Asia Symptom Criteria for Functional Dyspepsia Do Not Reliably 119 2 Distinguish Functional From Organic Disease. 2020, 11, e00278 118 ImplementaB da Campanha Choosing Wisely no Internato de Claica Maica. 2020, 44, Prevalence and Endoscopic Findings of <i&gt;Helicobacter pylori&lt;/i&gt; Infection among 117 1 Dyspeptic Patients in Kenya. 2020, 10, 233-242

Helicobacter pylori Infection: When Should It Be Treated?. 2020, 81-102

116

| 115 | Chronic Disease Management. <b>2020</b> , 143-167  |     |   |
|-----|--|-----|---|
| 114 | Implementation of the Choosing Wisely Campaign at a Medical Clinic Internship. 2020, 44,   |     |   |
| 113 | Dyspepsia: Overview and Treatment Options. <b>2020</b> , 181-193   |     |   |
| 112 | [Functional diseases of the gastrointestinal tract in the context with overlapping functional disorders: current status of the problem]. <b>2020</b> , 92, 111-118   |     | 2 |
| 111 | Protocolo diagn⊞tico y terapŪtico del paciente con dispepsia. <b>2020</b> , 13, 98-101   |     |   |
| 110 | Modern aspects of the pathogenesis and treatment of dyspepsia. <b>2020</b> , 40-46   |     | O |
| 109 | Chapter 13: Heartburn and Dyspepsia. <b>2020</b> ,   |     |   |
| 108 | The Role of Proton Pump Inhibitors in the Management of Upper Gastrointestinal Disorders. <b>2018</b> , 14, 169-175  |     | 3 |
| 107 | Functional gastrointestinal disorders. Overlap syndrome Clinical guidelines of the Russian Scientific Medical Society of Internal Medicine and Gastroenterological Scientific Society of Russia. <b>2021</b> , 5-117     |     | 5 |
| 106 | Effect of a Persian metabolic diet on the functional dyspepsia symptoms in patients with postprandial distress syndrome: a randomized, double-blind clinical trial. <b>2021</b> ,  |     |   |
| 105 | Age is the only predictor for upper gastrointestinal malignancy in Chinese patients with uncomplicated dyspepsia: a prospective investigation of endoscopic findings. <b>2021</b> , 21, 441                              |     | 1 |
| 104 | Dyspepsia: when to endoscope?. <b>2021</b> , 11, 215-221   |     |   |
| 103 | A Review on Vessel Segmentation of X-Ray Coronary Angiography Images Based on Deep Learning. <b>2021</b> ,   |     |   |
| 102 | Improving Clinician-Patient Communication Alleviates Stigma in Patients With Functional Dyspepsia Receiving Antidepressant Treatment <b>2022</b> , 28, 95-103  |     | O |
| 101 | Effectivity of treatment for children with functional dyspepsia 2022, 12, 1467   |     | O |
| 100 | Gastritis, Esophagitis, and Peptic Ulcer Disease. <b>2022</b> , 1227-1236  |     |   |
| 99  | A Single Fasting Exhaled Methane Level Correlates With Fecal Methanogen Load, Clinical Symptoms and Accurately Detects Intestinal Methanogen Overgrowth <i>American Journal of Gastroenterology</i> , <b>2022</b> , 117, | 0.7 | О |
| 98  | Evidence-based clinical practice guidelines for functional dyspepsia 2021 <b>2022</b> , 57, 47   |     | 3 |

| 97                         | Ultrasonographic assessment of preoperative gastric volume in patients with dyspepsia: a prospective observational study <b>2022</b> , 22, 21  | 1   |
|----------------------------|--|-----|
| 96                         | Development and Validity Assessment of a Self-evaluation Questionnaire for Functional Dyspepsia: A Multicenter Prospective Study in Korea <b>2022</b> , 28, 111-120  | O   |
| 95                         | Impact of helicobacter pylori on human physiology and digestive disorders. <b>2022</b> , 193-205   |     |
| 94                         | Modern approaches in treatment of helicobacteriosis in patients with peptic ulcer. <b>2022</b> , 7-13  | 1   |
| 93                         | Esophagogastroduodenoscopy in Patients Aged 75 Years and Older: A Single-Center Study <b>2022</b> , 14, e21846   | О   |
| 92                         | Primary and metastatic peritoneal surface malignancies <b>2021</b> , 7, 91   | 4   |
| 91                         | Quality in Barrett's Esophagus: Diagnosis and Management. <b>2022</b> ,  |     |
| 90                         | Approach to the patient with dyspepsia and related functional gastrointestinal complaints. <b>2022</b> , 560-566   |     |
| 89                         | Visceral pain. <b>2022</b> , 355-365   |     |
|                            |  |     |
| 88                         | An Easily Digestible Review of Helicobacter pylori Diagnostics. <b>2022</b> , 44, 51-61  | 0   |
| 88                         | An Easily Digestible Review of Helicobacter pylori Diagnostics. 2022, 44, 51-61  Evaluation of a Multidisciplinary Integrated Treatment Approach Versus Standard Model of Care for Functional Gastrointestinal Disorders (FGIDS): A Matched Cohort Study 2022, 1   | 0   |
|                            | Evaluation of a Multidisciplinary Integrated Treatment Approach Versus Standard Model of Care  |     |
| 87                         | Evaluation of a Multidisciplinary Integrated Treatment Approach Versus Standard Model of Care for Functional Gastrointestinal Disorders (FGIDS): A Matched Cohort Study 2022, 1  Peptic ulcer disease among dyspeptic patients at endoscopy unit, University of Gondar hospital,   | 1   |
| 8 <sub>7</sub><br>86       | Evaluation of a Multidisciplinary Integrated Treatment Approach Versus Standard Model of Care for Functional Gastrointestinal Disorders (FGIDS): A Matched Cohort Study 2022, 1  Peptic ulcer disease among dyspeptic patients at endoscopy unit, University of Gondar hospital, Northwest Ethiopia 2022, 22, 164  Evaluation of QOL in Patients with Dyspeptic Symptoms Who Meet or Do Not Meet Rome IV   | 1   |
| 87<br>86<br>85             | Evaluation of a Multidisciplinary Integrated Treatment Approach Versus Standard Model of Care for Functional Gastrointestinal Disorders (FGIDS): A Matched Cohort Study 2022, 1  Peptic ulcer disease among dyspeptic patients at endoscopy unit, University of Gondar hospital, Northwest Ethiopia 2022, 22, 164  Evaluation of QOL in Patients with Dyspeptic Symptoms Who Meet or Do Not Meet Rome IV Criteria 2021, 11,  Chinese herbal medicine for functional dyspepsia: a network meta-analysis of prokinetic-controlled  | 1   |
| 87<br>86<br>85<br>84       | Evaluation of a Multidisciplinary Integrated Treatment Approach Versus Standard Model of Care for Functional Gastrointestinal Disorders (FGIDS): A Matched Cohort Study 2022, 1  Peptic ulcer disease among dyspeptic patients at endoscopy unit, University of Gondar hospital, Northwest Ethiopia 2022, 22, 164  Evaluation of QOL in Patients with Dyspeptic Symptoms Who Meet or Do Not Meet Rome IV Criteria 2021, 11,  Chinese herbal medicine for functional dyspepsia: a network meta-analysis of prokinetic-controlled randomised trials 2021, 16, 140  | 1   |
| 87<br>86<br>85<br>84<br>83 | Evaluation of a Multidisciplinary Integrated Treatment Approach Versus Standard Model of Care for Functional Gastrointestinal Disorders (FGIDS): A Matched Cohort Study 2022, 1  Peptic ulcer disease among dyspeptic patients at endoscopy unit, University of Gondar hospital, Northwest Ethiopia 2022, 22, 164  Evaluation of QOL in Patients with Dyspeptic Symptoms Who Meet or Do Not Meet Rome IV Criteria 2021, 11,  Chinese herbal medicine for functional dyspepsia: a network meta-analysis of prokinetic-controlled randomised trials 2021, 16, 140  Functional dyspepsia: a multifaceted problem in gastroenterology. 2021, 93, 1539-1544  Diagnostic Evaluation of Gastric Motor and Sensory Disorders American Journal of | 1 2 |

| 79 | Association between infection and irritable bowel syndrome: a systematic review and meta-analysis <b>2021</b> ,   | 2 |
|----|---|---|
| 78 | The utility of a symptom model to predict the risk of oesophageal cancer 2022,  |   |
| 77 | Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance <b>2022</b> , e0025821   | 1 |
| 76 | Role of the duodenal microbiota in functional dyspepsia <b>2022</b> , e14372  | 1 |
| 75 | [Clinical management of autoimmune gastritis] 2022, 147, 451-459  |   |
| 74 | Functional dyspepsia symptom diary is correlated with other questionnaires and associated with severity in patients with functional dyspepsia: a multicenter, prospective observational study <b>2022</b> |   |
| 73 | Immune Activation in Functional Dyspepsia: Bystander Becoming the Suspect 2022, 16, 831761  | 0 |
| 72 | Dyspepsia: terminology, causes and risk factors, patient management. <b>2022</b> , 44-51  | 1 |
| 71 | Functional Dyspepsia. <b>2022</b> , 95-113  |   |
| 70 | Management of Helicobacter Pylori Infection and Effectiveness Rates in Daily Clinical Practice in Spain: 2010 <b>1</b> 019. <b>2022</b> , 11, 698   | О |
| 69 | Practical application of breath tests in disorders of gutBrain interaction. 2022, 65, 102244  | 0 |
| 68 | Hepatitis C viral clearance with coadministration of crushed sofosbuvir/velpatasvir and high-dose pantoprazole after liver transplantation.   |   |
| 67 | Rebuilding trust in proton pump inhibitor therapy. <b>2022</b> , 28, 2667-2679  | 0 |
| 66 | Trends in proton pump inhibitor use, reflux esophagitis, and various upper gastrointestinal symptoms from 2010 to 2019 in Japan. <b>2022</b> , 17, e0270252   |   |
| 65 | Menthacarin for long-term treatment of functional dyspepsia likesults from a clinical trial follow-up.  |   |
| 64 | Just Drink a Glass of Water? Effects of BicarbonateBulfateLalciumMagnesium Water on the GutLiver Axis. 13,  | 1 |
| 63 | Saam Acupuncture for Treating Functional Dyspepsia: A Feasibility Randomized Controlled Trial. <b>2022</b> , 2022, 1-11   |   |
| 62 | Efficacy of <i>H. pylori</i> eradication therapy on dyspeptic symptoms in childhood. <b>2022</b> , 100, 22-26   |   |

| 61 | Management of Helicobacter pylori infection: Guidelines of the Italian Society of Gastroenterology (SIGE) and the Italian Society of Digestive Endoscopy (SIED). <b>2022</b> ,  | 3     |
|----|---|-------|
| 60 | British Society of Gastroenterology guidelines on the management of functional dyspepsia. gutjnl-2022-32  | 27737 |
| 59 | The Impact of Proton Pump Inhibitors on the Development of Gastric Neoplastic Lesions in Patients With Autoimmune Atrophic Gastritis. 13,   | О     |
| 58 | Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. <b>2022</b> , 71, 1724-1762   | 25    |
| 57 | 配图 a helluva journey  |       |
| 56 | Diet for Functional Gastrointestinal Disorders/Disorders of Gut <b>B</b> rain Interaction. <b>2022</b> ,  | O     |
| 55 | ANALYSIS OF FUNCTIONAL AND CLINICAL SYMPTOMS IN PATIENTS WITH CLASSICAL AND MEDIATED HYPERSECRETORY DISEASES OF THE GASTROINTESTINAL TRACT. <b>2022</b> , 18, 44-54   |       |
| 54 | In adults with functional dyspepsia, what is the comparative effectiveness of PPIs versus H2 blockers on discomfort?. Publish Ahead of Print,   | O     |
| 53 | Quantification of prevalence, clinical characteristics, co-existence, and geographic variations of traditional Chinese medicine diagnostic patterns via latent tree analysis-based differentiation rules among functional dyspepsia patients. <b>2022</b> , 17, | О     |
| 52 | Current and Future Perspectives in the Diagnosis and Management of Helicobacter pylori Infection. <b>2022</b> , 11, 5086  | 1     |
| 51 | Distribution of upper gastro-intestinal pathology by endoscopic evaluation and assessment of H. pylori colonization in malnourished Bangladeshi population: A descriptive study.  | O     |
| 50 | DBCU-Net: Deep Learning Approach for Segmentation of Coronary Angiography Images.   | O     |
| 49 | Pathogenetic role of cholecystokinin in functional dyspepsia. <b>2022</b> , 12-19   | О     |
| 48 | Infl uence of blood motylin concentration on clinical symptomatics of functional dyspepsy. <b>2022</b> , 58-64  | O     |
| 47 | Dyspepsia with alarm symptoms in patients aged less than 60 years: Is upper gastrointestinal endoscopy justified in Indian scenario?.   | О     |
| 46 | Gastroparesis and functional dyspepsia: spectrum of gastroduodenal neuromuscular disorders or unique entities?. <b>2022</b> ,   | O     |
| 45 | External treatment of traditional Chinese medicine for functional dyspepsia in children: Protocol for a systematic review and network meta-analysis. <b>2022</b> , 101, e31597  | 1     |
| 44 | Clinical Efficacy and Mechanism of Transcutaneous Neuromodulation on Functional Dyspepsia. Publish Ahead of Print,  | O     |

| 43 | Comparing diagnostic performance of Cantonese-Chinese version of Rome IV criteria and a short Reference Standard for functional dyspepsia in China. <b>2022</b> , 22,     | 0 |
|----|---|---|
| 42 | Could an Increased Percentage of Immature Granulocytes Accompanying Dyspepsia Predict COVID-19?. <b>2022</b> , 58, 1460   | O |
| 41 | Psychotherapy appears to improve symptoms of functional dyspepsia and anxiety: systematic review with meta-analysis. 1-27   | 0 |
| 40 | Reduced mastication is a risk factor for Rome IV postprandial distress syndrome in patients investigated with upper endoscopy. <b>2022</b> , 46, 102032                   | O |
| 39 | Prevalence and factors associated with atrophic gastritis and intestinal metaplasia: A multivariate, hospital-based, statistical analysis. <b>2023</b> , 82, 102309       | 0 |
| 38 | Management of Helicobacter pylori infection.  | O |
| 37 | Diagnostic yield of upper gastrointestinal endoscopy in patients attending a UK centre with symptoms compatible with Rome IV functional dyspepsia. flgastro-2022-102268   | 0 |
| 36 | High discovery rate of duodenal and gastric eosinophilia in patients with unexplained moderate-severe abdominal symptoms: A prospective US multi-site study <b>2022</b> , | Ο |
| 35 | Priorities in choosing prokinetic for patients with functional dyspepsia: Focus on itopride. <b>2022</b> , 1, 28-32   | 0 |
| 34 | Community prevalence of Helicobacter pylori and dyspepsia and efficacy of triple therapy in a rural district of eastern Uganda. <b>2022</b> , 8, e12612                   | O |
| 33 | The treatment of functional dyspepsia: present and future. <b>2023</b> , 17, 9-20   | Ο |
| 32 | Prevalence of delayed gastric emptying in patients with gastroparesis-like symptoms.  | O |
| 31 | Up-front endoscopy maximizes cost-effectiveness and cost-satisfaction in uninvestigated dyspepsia. <b>2023</b> ,  | 0 |
| 30 | Uninvestigated dyspepsia: to scope or not to scope?. <b>2023</b> ,  | O |
| 29 | Probiotics in Functional Dyspepsia. <b>2023</b> , 11, 351   | 0 |
| 28 | Understanding neuroimmune interactions in disorders of gutBrain interaction: from functional to immune-mediated disorders. gutjnl-2020-320633                             | Ο |
| 27 | Dyspepsia, An Algorithmic Approach. <b>2023</b> ,   | Ο |
| 26 | Magnetic resonance imaging with a stress drinking test as a method of assessing the evacuation function of the stomach. <b>2023</b> , 110-116                             | Ο |

| 25 | Non-neoplastic disorders in an aging gut: concise review. <b>2023</b> , 35,  | 0 |
|----|--|---|
| 24 | Status of Drug Therapy for Functional Dyspepsia in Children. <b>2023</b> , 13, 4352-4359   | О |
| 23 | Research trends in the field of the gut-brain interaction: Functional dyspepsia in the spotlight 🖾 integrated bibliometric and science mapping approach. 17,   | 0 |
| 22 | DBCU-Net: deep learning approach for segmentation of coronary angiography images.  | O |
| 21 | Targeting the altered duodenal microenvironment in functional dyspepsia. 2023, 70, 102363  | О |
| 20 | Auricular Vagus Nerve Stimulation Improves Visceral Hypersensitivity and Gastric Motility and Depression-like Behaviors via Vago-Vagal Pathway in a Rat Model of Functional Dyspepsia. <b>2023</b> , 13, 253 | О |
| 19 | Clinical Implications of Low-grade Duodenal Eosinophilia in Functional Dyspepsia. 2023, 57, 362-369  | 0 |
| 18 | Educational innovations in the approach of outpatients to improve health literacy.   | О |
| 17 | Assessment and management of disorders of gutBrain interaction in patients with eating disorders. <b>2023</b> , 11,  | O |
| 16 | Relative Cost-effectiveness of Management Strategies for Uninvestigated Dyspepsia. <b>2023</b> ,   | О |
| 15 | Mistakes in the diagnosis and treatment of Helicobacter pylori infection in daily clinical practice.   | 0 |
| 14 | Approach to Disorders of Gut-Brain Interaction. <b>2023</b> , 98, 458-467  | О |
| 13 | Review article: Functional dyspepsial gastric disorder, a´duodenal disorder or a combination of both?. <b>2023</b> , 57, 851-860   | O |
| 12 | Capsaicin: A Novel Approach to the Treatment of Functional Dyspepsia.  | О |
| 11 | Critical appraisal of international guidelines for the management of Helicobacter pylori infection in case of dyspepsia. <b>2023</b> , 28,   | О |
| 10 | Novel insights in the pathophysiology and management of functional dyspepsia. 2023, 86, 68-73  | О |
| 9  | Neuromodulating agents in functional dyspepsia: a comprehensive review. 2023, 86, 49-57  | 0 |
| 8  | Food, Dietary Patterns, or Is Eating Behavior to Blame? Analyzing the Nutritional Aspects of Functional Dyspepsia. <b>2023</b> , 15, 1544  | O |

## CITATION REPORT

| 7 | Reply. <b>2023</b> ,   | О |
|---|--|---|
| 6 | Indian consensus statements on irritable bowel syndrome in adults: A guideline by the Indian<br>Neurogastroenterology and Motility Association and jointly supported by the Indian Society of<br>Gastroenterology. | O |
| 5 | A Malaysian consensus report on the diagnosis and treatment of Helicobacter pylori infection.  | 0 |
| 4 | Safety and efficacy of Xiaoyao-san for the treatment of functional dyspepsia: a systematic review and meta-analysis of randomized controlled trials. 14,   | O |
| 3 | Influence of proton pump inhibitor use on clinical outcomes of patients with inflammatory bowel disease. <b>2023</b> , 55,   | 0 |
| 2 | Helicobacter pylori infection. <b>2023</b> , 9,  | O |
| 1 | Esophageal Hypersensitivity and Functional Dyspepsia. <b>2023</b> , 69-75  | 0 |